Chief Commercial Officer

Ashley Kline

Ms. Kline is a seasoned commercial leader with more than 15 years of experience in the biopharmaceutical industry. She joined Palvella as Chief Commercial Officer in May 2025 with a strong track record of building and scaling high-performing commercial organizations—especially in rare disease.

Prior to Palvella, Ms. Kline served as Global Biotech Head and U.S. General Manager at Dompé Pharmaceuticals, where she led the successful launch of Oxervate®, a first-in-disease topical therapy for neurotrophic keratitis (NK)—a rare, serious, and progressive eye disease that previously had no FDA-approved therapies. Under her leadership, Oxervate surpassed $500 million in annual U.S. sales by the fifth year of launch and achieved profitability in the first year of launch, becoming one of the top-performing orphan drug launches of the past decade. Ms. Kline previously held senior commercial roles at Santen Pharmaceuticals, Adverum Biotechnologies, and Genentech. Before beginning her career in biotech, she was a consultant for Bain & Company, where she advised senior executives on customer-facing issues in a diverse set of industries.

Ms. Kline earned her M.B.A. from the Kellogg School of Management at Northwestern University with majors in Finance, Decision Science, and Analytical Consulting and a B.A., with distinction, from the University of North Carolina at Chapel Hill.